Obexelimab

{
  "id": "MLC-T-ONC-015581",
  "term": "Obexelimab",
  "field": "Oncology and biomedicine",
  "definition": "A humanized immunoglobulin G1 (IgG1) noncytolytic monoclonal antibody directed against the B-cell-specific cell surface antigen CD-19, Fc-engineered for increased affinity to Fc gamma receptor IIB (FcgRIIB; CD32B), with potential immunomodulatory activity. Upon administration, obexelimab simultaneously targets and binds to both CD19 and FcgRIIB expressed on the surface of B cells, and inhibits B-cell receptor (BCR) signaling and the activity of B cells without depleting the B-cells. This may alleviate manifestations of autoimmune diseases including systemic lupus erythematosus (SLE). CD19 and FcgRIIB, both expressed on the surface of B-cells, play important roles in BCR signaling, and B-cell activity and survival.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/obexelimab/"
}